FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205173173> ?p ?o ?g. }

• W3205173173 abstract "<h3>Introduction/Background*</h3> Cervical cancer is the fourth most common cause of cancer-related deaths in women worldwide. With screening for precancerous lesions and vaccination for preventive human papillomavirus (HPV), a survival improvement has been observed in these patients in developed countries. In recent years, U.S. Food and Drug Administration (FDA) approved pembrolizumab for the treatment of patients with advanced cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1. Herein, we present the first systematic review discussing the safety profile of this drug. <h3>Methodology</h3> A systematic literature search was performed on March 2021 according to PRISMA statement using PubMed, Embase, Scopus, CINAHL, Cochrane, Google Scholar, and Clinicaltrials.gov databases without any filters. The medical search terms (MeSH) utilized to conduct the search are, ‘ uterine cervical neoplasms’ AND ’Pembrolizumab’. After a detailed primary and secondary screening done by two members of 188 studies, only 4 studies were found that discussed the safety profile of pembrolizumab. <h3>Result(s)*</h3> A total of 337 patients, mean age 48 years (21-76) with advanced cervical cancer who had received a median range of 1-7 previous lines of therapies, were included. In all studies, pembrolizumab was used as a single agent with a regimen of 200mg IV every 3 weeks. Cumulative treatment related adverse effect (AE) was reported in 60% (n=201/337). Most common grade 1-2 AEs were hypothyroidism 9.2%(n=29/313), diarrhea 8%(n=22/337), fatigue 6.59% (n=22/337) and rash 7% (n= 10/141). Treatment related grade ≥ 3 adverse reaction was reported in 8.6%. Most common grade 3-4 AEs presented were transaminitis, neutropenia, rash, colitis, Guillain-Barré syndrome (GBS), and proteinuria. Also, 3.5% of patient population (n= 5/141) discontinued therapy due to treatment-related adverse events. Immune-mediated AEs were seen in 27% (n= 31/118). The most common immune-mediated AEs were hypothyroidism, hyperthyroidism, rash, colitis and GBS. <h3>Conclusion*</h3> While early-stage cervical cancer can be curable with surgery, prognosis of patients who recur remains poor, with limited treatment options. New effective treatments are therefore much needed in this setting. Pembrolizumab (Keytruda) monotherapy demonstrated manageable safety profile in patients with advanced cervical cancer. However, more randomized clinical trials are required to establish strong conclusions." @default.
• W3205173173 created "2021-10-25" @default.
• W3205173173 creator A5004349926 @default.
• W3205173173 creator A5023322506 @default.
• W3205173173 creator A5025126436 @default.
• W3205173173 creator A5025510150 @default.
• W3205173173 creator A5028159870 @default.
• W3205173173 creator A5035469744 @default.
• W3205173173 creator A5040010155 @default.
• W3205173173 creator A5042911120 @default.
• W3205173173 creator A5043026057 @default.
• W3205173173 creator A5047580018 @default.
• W3205173173 creator A5047681064 @default.
• W3205173173 creator A5058675387 @default.
• W3205173173 creator A5062276126 @default.
• W3205173173 creator A5062279447 @default.
• W3205173173 creator A5081328520 @default.
• W3205173173 creator A5081908748 @default.
• W3205173173 creator A5087005055 @default.
• W3205173173 date "2021-10-01" @default.
• W3205173173 modified "2023-09-25" @default.
• W3205173173 title "741 Safety Profile of Keytruda (pembrolizumab) for the treatment of patients with advanced PD-L1 positive cervical cancer" @default.
• W3205173173 doi "https://doi.org/10.1136/ijgc-2021-esgo.63" @default.
• W3205173173 hasPublicationYear "2021" @default.
• W3205173173 type Work @default.
• W3205173173 sameAs 3205173173 @default.
• W3205173173 citedByCount "0" @default.
• W3205173173 crossrefType "proceedings-article" @default.
• W3205173173 hasAuthorship W3205173173A5004349926 @default.
• W3205173173 hasAuthorship W3205173173A5023322506 @default.
• W3205173173 hasAuthorship W3205173173A5025126436 @default.
• W3205173173 hasAuthorship W3205173173A5025510150 @default.
• W3205173173 hasAuthorship W3205173173A5028159870 @default.
• W3205173173 hasAuthorship W3205173173A5035469744 @default.
• W3205173173 hasAuthorship W3205173173A5040010155 @default.
• W3205173173 hasAuthorship W3205173173A5042911120 @default.
• W3205173173 hasAuthorship W3205173173A5043026057 @default.
• W3205173173 hasAuthorship W3205173173A5047580018 @default.
• W3205173173 hasAuthorship W3205173173A5047681064 @default.
• W3205173173 hasAuthorship W3205173173A5058675387 @default.
• W3205173173 hasAuthorship W3205173173A5062276126 @default.
• W3205173173 hasAuthorship W3205173173A5062279447 @default.
• W3205173173 hasAuthorship W3205173173A5081328520 @default.
• W3205173173 hasAuthorship W3205173173A5081908748 @default.
• W3205173173 hasAuthorship W3205173173A5087005055 @default.
• W3205173173 hasBestOaLocation W32051731731 @default.
• W3205173173 hasConcept C121608353 @default.
• W3205173173 hasConcept C126322002 @default.
• W3205173173 hasConcept C141071460 @default.
• W3205173173 hasConcept C143998085 @default.
• W3205173173 hasConcept C197934379 @default.
• W3205173173 hasConcept C2777701055 @default.
• W3205173173 hasConcept C2778220009 @default.
• W3205173173 hasConcept C2778570526 @default.
• W3205173173 hasConcept C2780057760 @default.
• W3205173173 hasConcept C2781413609 @default.
• W3205173173 hasConcept C71924100 @default.
• W3205173173 hasConceptScore W3205173173C121608353 @default.
• W3205173173 hasConceptScore W3205173173C126322002 @default.
• W3205173173 hasConceptScore W3205173173C141071460 @default.
• W3205173173 hasConceptScore W3205173173C143998085 @default.
• W3205173173 hasConceptScore W3205173173C197934379 @default.
• W3205173173 hasConceptScore W3205173173C2777701055 @default.
• W3205173173 hasConceptScore W3205173173C2778220009 @default.
• W3205173173 hasConceptScore W3205173173C2778570526 @default.
• W3205173173 hasConceptScore W3205173173C2780057760 @default.
• W3205173173 hasConceptScore W3205173173C2781413609 @default.
• W3205173173 hasConceptScore W3205173173C71924100 @default.
• W3205173173 hasLocation W32051731731 @default.
• W3205173173 hasOpenAccess W3205173173 @default.
• W3205173173 hasPrimaryLocation W32051731731 @default.
• W3205173173 hasRelatedWork W2281121233 @default.
• W3205173173 hasRelatedWork W2418015830 @default.
• W3205173173 hasRelatedWork W2589510184 @default.
• W3205173173 hasRelatedWork W2953911854 @default.
• W3205173173 hasRelatedWork W3030932769 @default.
• W3205173173 hasRelatedWork W3103265772 @default.
• W3205173173 hasRelatedWork W3140601899 @default.
• W3205173173 hasRelatedWork W4200625667 @default.
• W3205173173 hasRelatedWork W4224862170 @default.
• W3205173173 hasRelatedWork W4285098856 @default.
• W3205173173 isParatext "false" @default.
• W3205173173 isRetracted "false" @default.
• W3205173173 magId "3205173173" @default.
• W3205173173 workType "article" @default.